Viewing Study NCT07279402


Ignite Creation Date: 2025-12-25 @ 3:39 AM
Ignite Modification Date: 2025-12-26 @ 2:23 AM
Study NCT ID: NCT07279402
Status: RECRUITING
Last Update Posted: 2025-12-12
First Post: 2025-12-01
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: TRIMPACT: Real-World First-Line Atezolizumab Use in Stage IV NSCLC With PD-L1 ≥50%
Sponsor: Antalya Training and Research Hospital
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module